Drugs / AD-2282
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06858865 | Jul → Aug 2025 | hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06747936 | Feb → Dec 2025 overdue | hyperlipoproteinemia | Addpharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-2282 | “AD-2281 Oral Tablet + AD-2282 Oral Tablet” NCT06858865 ↗ |
| Route | Oral | “PO, Once daily, 8weeks” NCT06747936 ↗ |